Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.
Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, Suttman E, Larson D, Branson C, McKee KE, Goelz L, Poon C, Tilley B, Kang UJ, Tansey MG, Luthra N, Tanner CM, Haus JM, Fantuzzi G, McFarland NR, Gonzalez-Latapi P, Foroud T, Motl R, Schwarzschild MA, Simuni T, Marek K, Naito A, Lungu C, Corcos DM; SPARX3-PSG Investigators. Patterson CG, et al. Among authors: tanner cm. Trials. 2022 Oct 6;23(1):855. doi: 10.1186/s13063-022-06703-0. Trials. 2022. PMID: 36203214 Free PMC article.
A responsive outcome for Parkinson's disease neuroprotection futility studies.
Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K; NET-PD Investigators. Elm JJ, et al. Among authors: tanner cm. Ann Neurol. 2005 Feb;57(2):197-203. doi: 10.1002/ana.20361. Ann Neurol. 2005. PMID: 15668964
Urate as a predictor of the rate of clinical decline in Parkinson disease.
Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators. Ascherio A, et al. Among authors: tanner cm. Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247. Arch Neurol. 2009. PMID: 19822770 Free PMC article. Clinical Trial.
Head injury, α-synuclein Rep1, and Parkinson's disease.
Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Meng C, Korell M, Roucoux DF, Hoppin JA, Sandler DP, Langston JW, Tanner CM. Goldman SM, et al. Among authors: tanner cm. Ann Neurol. 2012 Jan;71(1):40-8. doi: 10.1002/ana.22499. Ann Neurol. 2012. PMID: 22275250 Free PMC article. Clinical Trial.
Caffeine consumption and risk of dyskinesia in CALM-PD.
Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA; Parkinson Study Group. Wills AM, et al. Among authors: tanner cm. Mov Disord. 2013 Mar;28(3):380-3. doi: 10.1002/mds.25319. Epub 2013 Jan 21. Mov Disord. 2013. PMID: 23339054 Free PMC article. Clinical Trial.
Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.
Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Brundin P, et al. Among authors: tanner cm. J Parkinsons Dis. 2013 Jan 1;3(3):231-9. doi: 10.3233/JPD-139000. J Parkinsons Dis. 2013. PMID: 24018336 Free PMC article. Review.
337 results